Protagonist Therapeutics (Protagonist Therapeutics) Accounts Payable & Accrued Expense : $20.9 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Protagonist Therapeutics Accounts Payable & Accrued Expense?

Protagonist Therapeutics's quarterly accounts payable & accrued expense declined from Sep. 2023 ($21.5 Mil) to Dec. 2023 ($13.3 Mil) but then increased from Dec. 2023 ($13.3 Mil) to Mar. 2024 ($20.9 Mil).

Protagonist Therapeutics's annual accounts payable & accrued expense declined from Dec. 2021 ($32.2 Mil) to Dec. 2022 ($23.6 Mil) and declined from Dec. 2022 ($23.6 Mil) to Dec. 2023 ($13.3 Mil).

Protagonist Therapeutics Accounts Payable & Accrued Expense Historical Data

The historical data trend for Protagonist Therapeutics's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Protagonist Therapeutics Accounts Payable & Accrued Expense Chart

Protagonist Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

10.51

15.16

32.19

23.63

13.34

Protagonist Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															18.53	20.31	21.53	13.34	20.86

Protagonist Therapeutics Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Protagonist Therapeutics (Protagonist Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protagonist Therapeutics Inc (NAS:PTGX) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

7707 Gateway Boulevard, Suite 140, Newark, CA, USA, 94560

Website

https://www.protagonist-inc.com

Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.

Executives

Suneel Gupta	officer: Chief Development Officer	7707 GATEWAY BLVD., SUITE 140, NEWARK CA 94560
Patel Dinesh V Ph D	director, officer: President and CEO	C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035
Arturo Md Molina	officer: Chief Medical Officer	10990 WILSHIRE BLVD, SUITE 1200, LOS ANGELES CA 90024
Swisher Daniel N Jr	director	C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Lewis T Williams	director	C/O FIVE PRIME THERAPEUTICS, INC., TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Bryan Giraudo	director	7707 GATEWAY BOULEVARD, SUITE 140, NEWARK CA 94560
Harold E Selick	director
Sarah B. Noonberg	director	331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Sarah A O'dowd	director	3185 LAURELVIEW COURT, FREMONT CA 94538
William D. Waddill	director	C/O CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SO. SAN FRANCISCO CA 94080
Asif Ali	officer: Chief Financial Officer	7707 GATEWAY BLVD., SUITE 140, NEWARK CA 94560
Donald A. Kalkofen	officer: Chief Financial Officer	7707 GATEWAY BOULEVARD, SUITE 140, NEWARK CA 94560
David Y Liu	officer: Chief Scientific Officer	C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035
Chaitan Phd Khosla	director	3832 BAY CENTER PLACE, HAYWARD CA 94545
Richard S Shame	officer: Chief Medical Officer	C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035